Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has 7 years of Current Deferred Revenue data on file, last reported at $34.4 million in Q4 2025.

• On a quarterly basis, Current Deferred Revenue rose 153.13% year-over-year to $34.4 million in Q4 2025; TTM through Dec 2025 was $34.4 million, a 153.13% increase from a year earlier, with the FY2025 full-year figure at $34.4 million, up 153.13% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $34.4 million, down from $37.2 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for KYMR reached as high as $152.6 million in Q1 2021 and fell as low as $11.5 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $55.9 million across 5 years, with a median of $38.6 million in 2025.
• Across the five-year window, Current Deferred Revenue slumped 75.16% in 2024 and soared 153.13% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $101.0 million in 2021, then sank by 65.1% to $35.3 million in 2022, then jumped by 54.99% to $54.7 million in 2023, then slumped by 75.16% to $13.6 million in 2024, then surged by 153.13% to $34.4 million in 2025.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $34.4 million in Q4 2025, $37.2 million in Q3 2025, and $40.0 million in Q2 2025.